To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCL0037 | CS23064 Featured |
CS23064 is a cholesterol-containing ionizable lipid for three-component lipid nanoparticles and mRNA vaccine delivery. Its imidazole-containing amino headgroup is connected to a cholesteryl ester and a branched lipid ester, enabling formulation with DOPE and DMG-PEG2000 without a separate cholesterol component. CS23064-based LNP1 supports mRNA expression in Hep3B cells and predominantly local expression after intramuscular administration in mice. SARS-CoV-2 S-protein mRNA vaccination with LNP1 elicits antigen-specific antibody and CD8+ T-cell responses in mice.
More description
|
|
| DCL0028 | HX1 Featured |
HX1 is a hydroxyzine-derived ionizable lipid with acetal-containing tails, studied as a component of lipid nanoparticles (LNPs) for RNA delivery to the central nervous system. In a preclinical study, HX1-containing LNPs supported reporter mRNA expression and functional CRISPR-mediated genome editing in the mouse brain. The researchers also detected luciferase expression in the brain of a non-human primate after delivery of reporter mRNA. In a separate mouse model, HX1-containing LNPs carrying Il10 mRNA reduced markers of inflammation and tissue injury following brain irradiation.
More description
|
|
| DCC4281 | Psb-10129 Featured |
Positive modulator of ATP effects at P2X2 receptors
More description
|
|
| DCL0033 | Acuitas Lipid 17 (ALC-0315 retro-ester) Featured |
Acuitas Lipid 17 (ALC-0315 retro-ester) is an ester-linked ionizable amino lipid identified as Compound 17 in Acuitas patent WO2017075531A1. It contains a 4-hydroxybutyl tertiary-amine head group and two branched 2-hexyldecyl ester tails, with reversed ester orientation relative to ALC-0315. It is intended for research on lipid nanoparticles and mRNA delivery.
More description
|
|
| DCL0031 | LQ089 Featured |
LQ089 is a tertiary-amine ionizable lipid reported in patent CN118506877A for mRNA lipid-nanoparticle research. In the cited luciferase-mRNA formulation, LQ089 LNPs showed higher whole-body reporter-expression exposure than the MC3 comparator after intravenous administration in mice. These preclinical results apply to the reported complete formulation and study conditions.
More description
|
|
| DCL0032 | DPG-PEG 2000 (16:1) Featured |
DPG-PEG 2000 (16:1) is a PEGylated lipid with two unsaturated C16 acyl chains and a methoxy-PEG segment. It is used as a PEG-lipid component in lipid-carrier research.
More description
|
|
| DCL0030 | W3 Featured |
W3 is a vitamin E-modified, SM-102-derived ionizable lipid studied for mRNA delivery. The published study reports reduced inflammatory responses and intracellular oxidative stress with W3-containing LNPs relative to SM-102 LNPs. An optimized W3 formulation, termed sW3, was investigated for spleen-associated mRNA expression and antitumour vaccination. These preclinical findings apply to the complete formulations and experimental conditions; they do not establish clinical safety or the performance of isolated W3.
More description
|
|
| DCL0026 | OL-56 (HO-PEG-Ste) Featured |
OL-56 (HO-PEG-Ste) is a hydroxyl-terminated PEG stearate for research on PEG-lipid components of lipid nanoparticles. It combines a PEG chain with a single C18 fatty-acid anchor through an ester linkage.
More description
|
|
| DC31692 | Fludrocortisone Featured |
Fludrocortisone is a synthetic corticosteroid with moderate glucocorticoid potency and much greater mineralocorticoid potency. Therapeutically, it is used for its mineralocorticoid activity and not for its glucocorticoid activity. Fludrocortisone has been used in the treatment of cerebral salt wasting syndrome. However, it is used primarily to replace the missing hormone aldosterone in various forms of adrenal insufficiency such as Addison's disease and the classic salt wasting (21-hydroxylase deficiency) form of congenital adrenal hyperplasia. Due to its effects on increasing Na+ levels, and therefore blood volume, fludrocortisone is the first line of treatment for orthostatic intolerance and postural orthostatic tachycardia syndrome (POTS). It can be used to treat low blood pressure. Fludrocortisone is also used as a confirmation test for diagnosing Conn's syndrome (aldosterone producing-adrenal adenoma).
More description
|
|
| DC68259 | Ki6783 Featured |
|
|
| DC68258 | PPARγ agonist-27 Featured |
PPARγ agonist-27 is an orally active and blood-brain barrier-penetrant PPARγ agonist with EC50 = 4.7 μM. PPARγ agonist-27 activates PPARγ, upregulates downstream Klotho gene expression, and simultaneously inhibits mitochondrial ROS production. PPARγ agonist-27 can be used in research related to neurological diseases such as Alzheimer's disease.
More description
|
|
| DC68257 | 3-((S)-3-aminopiperidin-1-yl)-5-(3,5-dimethylisoxazol-4-yl)-3-phenylindolin-2-one Featured |
|
|
| DC68256 | 2-(5,9-dimethyl-7-oxo-3-phenyl-7H-furo[3,2-g]chromen-6-yl)acetic acid Featured |
|
|
| DC68255 | Lorglumide sodium salt Featured |
Lorglumide sodium (CR-1409 sodium) is an orally active Cholecystokinin Receptor antagonist. Lorglumide sodium inhibits pancreatic cancer cell proliferation, induces G0/G1 phase arrest and apoptosis, and downregulates MMP-2. Lorglumide sodium inhibits gastrin-stimulated Ornithine decarboxylase activity and DNA synthesis, and shows low CCKA/CCKB selectivity. Lorglumide sodium blocks Caerulein (HY-A0190)-induced exocrine pancreatic secretion and pancreatic tissue hyperplastic changes in rats, and inhibits gallbladder emptying induced by exogenous and endogenous CCK in mice.
More description
|
|
| DC68254 | N-(2-((1-methylpyrrolidin-3-yl)oxy)pyridin-3-yl)isonicotinamide hydrochloride Featured |
|
|
| DC68253 | 3-(4-chlorophenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione Featured |
|
|
| DC68252 | (E)-N-(4-oxocyclohexyl)-3-(3,4,5-trimethoxyphenyl)acrylamide Featured |
|
|
| DC68251 | Cinepazide Impurity F Featured |
|
|
| DC68250 | N-Desmethyl Zopiclone Hydrochloride Featured |
|
|
| DC68249 | 4-(3-(1-(4--Cyano-3-(trifluoromethyl)phenyl)methyl-4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazolin-7-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile Featured |
|
|
| DC68248 | DCN1-IN-2 Featured |
DCN1-IN-2 is a DCN1 inhibitor with an IC50 value of 2.96 nM. DCN1-IN-2 can alleviate Ang II/TGFβ-induced activation of cardiac fibroblasts.
More description
|
|
| DC68247 | 6a-hydroxy-3-(2-hydroxy-5-methylphenyl)-5-(tetrahydro-2H-pyran-4-yl)-4-(4-(trifluoromethyl)phenyl)-3a,4,5,6a-tetrahydropyrrolo[3,4-c]pyrazol-6(1H)-one Featured |
|
|
| DC68246 | N-((8-hydroxyquinolin-7-yl)(p-tolyl)methyl)pentanamide Featured |
|
|
| DC68245 | D359-0396 Featured |
D359-0396 is an orally active NLRP3 inflammasome inhibitor. D359-0396 inhibits pyroptosis and IL-1β release in macrophages. D359-0396 also inhibits the oligomerization of NLRP3, ASC and the cleavage of GSDMD.
More description
|
|
| DC68243 | Atrazine-desethyl Featured |
Atrazine-desethyl is a triazine herbicide.
More description
|
|
| DC68244 | 6-(4-isopropylphenyl)-7,9-dimethyl-11-phenyl-6,7-dihydropyrimido[4',5':3,4]pyrrolo[1,2-a]quinoxaline-8,10(5H,9H)-dione Featured |
|
|
| DC68242 | (E)-6-(4-(4-ethylphenyl)but-1-en-1-yl)-2,3-dihydro-1H-inden-1-one Featured |
|
|
| DC71057 | Indoramin Featured |
Indoramin is an orally active antihypertensive agent. Indoramin is also selective for the α1A-adrenoceptor.
More description
|
|
| DC43294 | PF-429242 dihydrochloride Featured |
Novel subtilisin kexin isozyme-1/site-1 (SKI-1/S1P) protease inhibitor
More description
|
|
| DC10951 | MPT0E028 Featured |
MPT0E028 is a potent HDAC inhibitor that inhibits nuclear HDAC activity with IC50 of 11.1 nM in HeLa cells, 9-30 times more potent than SAHA.
More description
|
|